Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|February 14, 2013
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanomaJ S Wilmott, A M Menzies, L E Haydu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanomaJ H Lee, G V Long, S Boyd, et al.
Oncoimmunology|October 21, 2016
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanomaE Liniker, A M Menzies, B Y Kong, et al.
ESMO Open|May 26, 2026
Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02CM Tetzlaff, J M Taube, G V Long, et al.
British Journal of Cancer|June 12, 2014
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanomaM S Carlino, L E Haydu, H Kakavand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2019
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patientsJ H Lee, R P Saw, J F Thompson, et al.
Cancer Immunology, Immunotherapy : CII|August 22, 2023
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infectionsC Schmitt, E P Hoefsmit, T Fangmeier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2014
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trialA M Menzies, M T Ashworth, S Swann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanomaA M Menzies, S N Lo, R P M Saw, et al.
ESMO Open|February 26, 2023
Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee surveyH Linardou, A A Adjei, J Bajpai, et al.
Pageof 4